Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PNMT | P11086 | 8/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257552 | 1.00 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL2857664 | 0.84 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL28239780 | 0.81 | PNMT (0.47) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL6966089 | 0.80 | PNMT (0.50) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL7008122 | 0.80 | PNMT (0.47) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL13062867 | 0.78 | PNMT (0.44) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL27897828 | 0.78 | PNMT (0.45) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL8247179 | 0.77 | PNMT (0.57) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL10293160 | 0.77 | GAA (0.54) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL6371190 | 0.77 | PNMT (0.50) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1142162-C | Bicyclic oxazolidinones as antibacterial agents | �������Ŷ���Լ��������˾ | 2004-03-17 | — | — | CN | disclosed |
| EP-1181288-B1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | UPJOHN CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN | 2002-10-03 | — | — | US | disclosed |
| CN-1353709-A | Bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UP JOHN CO (US) | 2002-06-12 | — | — | CN | disclosed |
| US-6387896-B1 | GRAMNEGATIVE, GRAMPOSITVE BACTERIA | PHARMACIA & UPJOHN CO. | 2002-05-14 | — | — | US | disclosed |
| EP-1181288-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073301-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | OXA1L, MRPL21, RPS4Y1 | ALDH1A1 1430/4885SMN1; SMN2 3570/4885PNMT 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.